Frazier-Backed Mavupharma Scores $20M to Fund STING Program Post author:Sam Post published:November 28, 2017 Post category:BioPharma The Series A funding will be used primarily to advance Mavu’s lead drug candidates into the clinic. Source: BioSpace You Might Also Like Bay Area's Atara Biotherapeutics Leases Huge Space in SoCal April 19, 2017 Bioverativ Execs Snagged a Nice Payday After Sanofi Deal February 8, 2018 Belgium Biotech Ablynx Files For $150 Million U.S. IPO Right After Phase III Boost October 2, 2017